Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of Ampreloxetine in Healthy Subjects
NCT04688632Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH) (3 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: QT interval corrected using Fridericia's formula at Day 15. Started Jan 2021; status: completed.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on NCT04688632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04688632.